Although pancreatic cancer is the number one killer, but its difficult early diagnosis and daunting. Beijing Union Medical College Hospital Medicine has just completed digest an important research allows people to fear diminished. The study results show that the joint stool K-ras oncogene and tumor suppressor gene p53 mutation detection, as well as tumor markers CA19-9 test, it is possible early detection of pancreatic cancer. In the recently held directly under the Ministry of Health (tube) units clinical disciplines in the assessment of key projects inspection, the assessment of the study was highly appraised by experts.
     In recent years, the global incidence of pancreatic cancer are increasing year by year. Over the years both at home and abroad no breakthrough in the diagnosis. In patients attending 3 / 4 is already late, the five-year survival rate of less than 5%. If input in the early diagnosis and treatment, the five-year survival rate of 20% to 50%. Therefore, the study of new screening and diagnostic means to improve the early detection rate of pancreatic cancer is the key to conquest.
     With the support of funds from 1997, the Beijing Union Medical College Hospital digestive medicine to land Star team, headed by Professor Early diagnosis of pancreatic cancer a comprehensive and in-depth exploration. Their study found that the duodenal cholangiopancreatography has the highest sensitivity and accuracy of the diagnosis; pancreatic cancer multiple oncogenes or tumor suppressor gene and protein anomalies very prominent. In the K-ras, P53 and P16 are two or more abnormal gene for 18 percent to 47 percent, while the absence of such chronic pancreatitis; stool DNA extraction through an improved method will be significantly higher than that reported in literature abroad PCR expansion by success rate. On this basis, the combined application of manure K-ras mutations and P53 mutation detection, diagnosis of pancreatic cancer sensitivity of up to 93.2%, if the above two with the detection of a tumor marker CA19-9 joint testing, diagnostic specificity of up to 85% to 100%; confirmed by surgery and pathology of T1 (tumor confined to the pancreas, there is no lymph node metastases) patients with pancreatic juice and feces K-ras mutation rate and P53 mutation rate and T2 more than similar patients . The aforementioned study, they concluded, the joint stool K-ras, p53 mutation detection and CA19-9 test, it is possible in the early detection of pancreatic cancer.
     It is learned that the experts will carry out the next stage of pancreatic cancer in the high-risk population (aged 45 and above, the new, diabetes, chronic pancreatitis, smoking, family history of cancer) for epidemiological investigation and follow-up to verify their screening method introduced .